Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. OneSource Specialty Pharma's Revenue for the
three
months ended in Jun. 2026 was ₹4,490 Mil. OneSource Specialty Pharma's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹6,902 Mil.
Hence, OneSource Specialty Pharma's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.65.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
OneSource Specialty Pharma Receivables Turnover Related Terms
OneSource Specialty Pharma Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONESOURCE vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, OneSource Specialty Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OneSource Specialty Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OneSource Specialty Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where OneSource Specialty Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OneSource Specialty Pharma (NSE:ONESOURCE) has a Receivables Turnover of 0.65 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on OneSource Specialty Pharma and its competitors. According to the industry distribution chart, OneSource Specialty Pharma ranks #683 out of 847 companies in the Biotechnology industry, placing it in the top 80.6%.
Is OneSource Specialty Pharma's Receivables Turnover too high?
OneSource Specialty Pharma's current Receivables Turnover is 0.65. The Biotechnology industry median Receivables Turnover is 5.28. OneSource Specialty Pharma's value of 0.65 is 87.7% below this industry median. Based on the distribution chart, OneSource Specialty Pharma ranks #683 out of 847 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OneSource Specialty Pharma ranks #683 out of 847 companies for Receivables Turnover. This places OneSource Specialty Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.28. OneSource Specialty Pharma's value of 0.65 is 87.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OneSource Specialty Pharma's current Receivables Turnover of 0.65 is 87.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on OneSource Specialty Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OneSource Specialty Pharma's current Receivables Turnover is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (NSE:ONESOURCE) has a current Receivables Turnover of 0.65. The current Receivables Turnover is 0.65 and 87.7% below the Biotechnology industry median of 5.28. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For OneSource Specialty Pharma (NSE:ONESOURCE), the current Receivables Turnover is 0.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score
Get the complete analysis for NSE:ONESOURCE
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONESOURCE has been successfully added to your 
